A previous study demonstrated that MCC950 (10 mg/kg) can successfully reduce myocardial fibrosis and IL-1β levels when given three times to patients with hypertension caused by angiotensin II infusion (174). This evidence concerns the gene IL1B and hypertensive disorder.